Research Article
Comparing the Efficacy and Safety of Induction Therapies for the Treatment of Patients with Proliferative Lupus Nephritis in South Africa
Table 2
Histopathological data and complications associated with both treatment groups.
| | | IVCYC (n = 65) | MMF (n = 19) | Total (n = 84) | value |
| | Number of glomeruli (median) (IQR) | 13 (9–16) | 18 (12–26) | 14 (10–18) | 0.01 | | Crescents % (IQR) | 3.8 (0.0–32.4) | 0.0 (0.0–10.0) | 0.0 (0.0–28.6) | 0.03 | | Sclerosed glomeruli % (IQR) | 0.0 (0.0–5.5) | 0.0 (0.0–10.0) | 0.0 (0.0–5.5) | 0.59 | | Interstitial fibrosis n (%) | 32 (50.0) | 7 (36.8) | 39 (47.0) | 0.31 | | ISN class | | III | 28 (43.1) | 8 (42.1) | 36 (42.9) | 0.49 | | IV | 25 (38.5) | 10 (52.6) | 35 (41.7) | | III + V | 2 (3.1) | 0 | 2 (2.4) | | IV + V | 10 (15.4) | 1 (5.3) | 11 (13.1) | | IgG deposits | | 0 | 15 (23.8) | 4 (21.1) | 19 (23.2) | 0.80 | | 1 | 12 (19.1) | 2 (10.5) | 14 (17.1) | | 2 | 23 (36.5) | 8 (42.1) | 31 (37.8) | | 3 | 13 (20.6) | 5 (26.3) | 18 (21.9) | | IgM deposits | | 0 | 11 (17.6) | 6 (31.6) | 17 (20.7) | 0.04 | | 1 | 13 (20.6) | 1 (5.3) | 14 (17.1) | | 2 | 24 (38.1) | 3 (15.8) | 27 (32.9) | | 3 | 15 (23.8) | 9 (47.4) | 24 (29.3) | | IgA deposits | | 0 | 34 (54.0) | 10 (52.6) | 44 (53.7) | 0.21 | | 1 | 18 (28.6) | 2 (10.5) | 20 (24.4) | | 2 | 7 (11.1) | 4 (21.1) | 11 (13.4) | | 3 | 4 (6.4) | 3 (15.8) | 7 (8.5) | | C3 deposits | | 0 | 5 (7.8) | 2 (10.5) | 7 (8.4) | 0.61 | | 1 | 10 (15.6) | 4 (21.1) | 14 (16.9) | | 2 | 20 (31.3) | 3 (15.8) | 23 (27.7) | | Complications (%) | | Infection | 20 (30.8) | 3 (15.8) | 23 (27.3) | 0.20 | | Diabetes mellitus | 4 (6.15) | 0 (0.0) | 4 (4.76) | 0.57 | | TB | 2 (3.1) | 0 (0.0) | 2 (2.4) | 0.22 | | Death | 14 (21.5) | 1 (5.3) | 15 (17.9) | 0.17 |
|
|
IVCYC: intravenous cyclophosphamide; MMF: mycophenolate mofetil; IgG: immunoglobulin G, IgM: immunoglobulin M; IgA: immunoglobulin A; C3: complement 3; grading of deposits (0–none, 1–mild, 2–moderate, and 3–severe); IQR: interquartile range; Tb: tuberculosis.
|
